Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

Digital Asset Direct by Cardiol Therapeutics

Vancouver, BC | December 16, 2022 09:26 AM Pacific Standard Time

Cardiol Therapeutics CEO David Elsley said the company has announced the beginning of a Phase II open-label pilot study which will investigate the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis. Elsley told Proactive the study will evaluate the use of CardiolRx as a novel therapy for pericarditis. It is expected to enroll 25 patients at clinical centers in the United States that specialize in pericarditis care.

Contact Details

Proactive Canada

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com